Senores Pharmaceuticals' board has approved a proposal to vary the utilisation of unutilised Initial Public Offer (IPO) proceeds amounting to ₹1000.16 million. This decision, taken on June 29, 2026, involves reallocating a portion of the total primary IPO proceeds, which stood at ₹5000.00 million. The move aims to optimise the deployment of capital raised during the public issue, pending necessary approvals.

The approval was granted during a board meeting convened on the recommendation of the Audit Committee. The meeting commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M. (IST) on the same day. The variation in fund utilisation is not immediately effective and requires the consent of the company's shareholders.

Shareholders will vote on the proposal through a postal ballot mechanism. This procedural step ensures that the reallocation of funds aligns with the interests of the investors and complies with regulatory requirements. The specific details regarding the new deployment avenues for the funds were not disclosed in the regulatory filing.

The intimation regarding the board meeting outcome has been submitted to BSE Limited and the National Stock Exchange of India Limited. The company scrip is listed under the code 544319 on the BSE and trades with the symbol SENORES on the NSE. The information is also available on the company's official website.

Financial Overview of IPO Proceeds

Senores Pharmaceuticals Limited relieved Company Secretary Vinay Kumar Mishra from his duties effective the close of business hours on June 10, 2026. The company informed the stock exchanges that the relief follows his earlier resignation intimation dated May 14, 2026.

In accordance with Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has designated specific Key Managerial Personnel (KMP) to determine the materiality of events and information for disclosures to the exchanges.

The authorized personnel include Managing Director Mr. Swapnil Jatinbhai Shah and Whole Time Director and Chief Financial Officer Mr. Deval Rajnikant Shah. The contact details for the Managing Director have been provided to facilitate necessary communications.

The company confirmed that the requisite information, including the copy of the resignation letter, was previously submitted to the exchanges as per SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Authorized Key Managerial Personnel